Sleep Trial to Prevent Alzheimer's Disease

Phase 2 Recruiting 120 enrolled University of Minnesota Good Ventures · collab Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

Timeline

Start: 2022-05-25
Primary completion: 2028-05
Completion: 2028-05

Publications

Noh MY, Kwon HS, Kwon MS, Nahm M, Jin HK, Bae JS, Kim SH. Biomarkers and therapeutic strategies targeting microglia in neurodegenerative diseases: current status and future directions. Mol Neurodegener. 2025 Jul 10;20(1):82. doi: 10.1186/s13024-025-00867-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Suvorexant	Small molecule	20 mg	—

Sleep Trial to Prevent Alzheimer's Disease

Summary

Timeline

Publications

Drugs

Indications